Adherence to highly active antiretroviral therapy in a tertiary care hospital in West Bengal, India

Abstract

Although overall adherence was high, the factors that affect nonadherence can be addressed with proper counselling and motivation of patients and their family members. Adherence to HAART could delay the progression of this lethal disease and minimise the risk of developing drug resistance.

References

Page 1

	Year	Citations
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection David L. Paterson, Susan Swindells, Jeffrey Mohr, Annals of Internal Medicine	2000	3.3K
Sample Size Determination in Health Studies: A Practical Manual. P. A. Lachenbruch, Stephen K. Lwanga, S. Lemeshow Journal of the American Statistical Association Medical StatisticSample Size DeterminationEpidemiologyHealth Studies	1991	2.1K
Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments Margaret A. Chesney, Jeannette R. Ickovics, Donald B. Chambers, AIDS Care	2000	1.4K
Correction: Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection Annals of Internal Medicine ImmunodeficienciesPopulation Health SciencesPharmacotherapyLogistic AnalysisHiv/aids Counselling	2002	506
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up Robert S. Hogg, Katherine Heath, David R. Bangsberg, AIDS	2002	426
Adherence is not a barrier to successful antiretroviral therapy in South Africa Catherine Orrell, David R. Bangsberg, Motasim Badri, AIDS	2003	342
Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence Sharon Mannheimer, John P. Matts, EE Telzak, AIDS Care Quality Of LifeFamily MedicineLife AssessmentMental HealthHiv-infected Individuals	2004	338
Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia Alemayehu Amberbir, Kifle Woldemichael, Sofonias Getachew, BMC Public Health	2008	236
Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 6 and 26 Hiroyuki Gatanaga, Tsunefusa Hayashida, K. Tsuchiya, Clinical Infectious Diseases	2007	222
Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors Franco Maggiolo, Laura Ravasio, D Ripamonti, Clinical Infectious Diseases	2004	222

Page 1